|
OEP's business development division is focused on the goals of introducing a diverse range of innovative products and expanding its overseas markets |
|---|
|
The division actively seeks products of major international firms for distribution and opportunities for development cooperation. Currently, OEP works closely with the following international firms: |
|
Obtained the exclusive rights of ASC-J9 acne cream in Taiwan, Korea, Australia, New Zealand, and Southeast Asia from AndroScience. The phase II clinical trial is completed and promising, the development project plan to move forward |
|
Cooperated with French company Besins for long periods, obtaining exclusive rights to sell the company’s hormone products in Taiwan’s market |
|
Signed agreement with Italian Chiesi Pharmaceutical Company for exclusive rights of Foster® and Trimbow® in Taiwan, Malaysia, Singapore and Philippines. Foster® was approved in Taiwan and covered by National Healthcare Insurance since 2010 and also approved in above countries since 2011 |
|
Authorized by Switzerland company Debiopharm to sell its cancer drugs in Taiwan and Southeast Asia |
|
Signed agreement wihth HRA pharma, obtained the exclusive rights of Ella®/Esmya, new mechanism drug to treat uterine fibroids, which has approved by TFDA |
|
Cooperated with French company Pierre Fabre for long periods, obtaining exclusive rights to sell the company’s anti-cancer products in Taiwan and Southeast Asia |
|
Signed a cooperation agreement with Plethora Solutions Limited in 2018, officially acquiring exclusive distribution rights for Fortacin, premature ejaculation treatment, in Taiwan and Southeast Asia. Dossier is under preparing for Taiwan FDA submission |
|
Obtained permit since 2001 for exclusive rights for the antihypertensive drug Zanidip of an Italian pharmaceutical company Recordati in Taiwan’s market |
|
Entered cooperative agreement with Second Sight in 2016, acquiring exclusive distribution rights for the Argus II Retinal Prosthesis System in Taiwan and obtained permission to sell in Taiwan |
|
Exclusively distributed the Company’s niche generic drug for the treatment of blood tumor in Taiwan and Philippine markets |
|
Signed a cooperative agreement with American company TissueTech in 2016, officially acquiring exclusive rights for the company’s next series of opthalmologic tissue products in Asia Pacific. Aminograft has received marketing authorization in Taiwan |
|
For more information, please contact： licensingin@mail.oep.com.tw |
|
 |
